Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.
GHRH
GHRH antagonist
SARS-CoV-2 spike protein
inflammation
macrophages
peripheral blood mononuclear cells (PBMC)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
05
2023
accepted:
24
07
2023
medline:
1
9
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
epublish
Résumé
COVID-19 is characterized by an excessive inflammatory response and macrophage hyperactivation, leading, in severe cases, to alveolar epithelial injury and acute respiratory distress syndrome. Recent studies have reported that SARS-CoV-2 spike (S) protein interacts with bacterial lipopolysaccharide (LPS) to boost inflammatory responses
Identifiants
pubmed: 37649486
doi: 10.3389/fimmu.2023.1231363
pmc: PMC10462983
doi:
Substances chimiques
GHRH(1-29)NH2, (PhAc-Ada)(0)-Tyr(1), Arg(2), Fpa(5,6), Ala(8), Har(9), Tyr(Me)(10), His(11), Orn(12,) Abu(15), His(20), Orn(21), Nle(27), Arg(28), Har(29)-
0
Growth Hormone-Releasing Hormone
9034-39-3
Lipopolysaccharides
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1231363Informations de copyright
Copyright © 2023 Granato, Gesmundo, Pedrolli, Kasarla, Begani, Banfi, Bruno, Lopatina, Brizzi, Cai, Sha, Ghigo, Schally and Granata.
Déclaration de conflit d'intérêts
AS, WS and RC are co-inventors on the patents for GHRH agonists, assigned to the University of Miami and Veterans Affairs Medical Center. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3755-60
pubmed: 21321192
Endocrine. 2021 May;72(2):349-355
pubmed: 33860882
Nat Rev Nephrol. 2021 Jan;17(1):46-64
pubmed: 33077917
Intensive Care Med Exp. 2020 Dec 7;8(1):72
pubmed: 33284413
J Mol Cell Biol. 2023 Feb 7;14(9):
pubmed: 36240490
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
J Immunol Methods. 2016 Mar;430:64-70
pubmed: 26826276
Cancers (Basel). 2021 Aug 05;13(16):
pubmed: 34439107
Endocrinology. 1995 Sep;136(9):4147-50
pubmed: 7649123
Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):692-7
pubmed: 9892695
Int J Mol Sci. 2022 Sep 24;23(19):
pubmed: 36232554
Peptides. 2017 Mar;89:60-70
pubmed: 28130121
J Endocrinol Invest. 2016 Jul;39(7):721-7
pubmed: 26891937
Science. 1982 Nov 5;218(4572):585-7
pubmed: 6812220
Immunology. 2009 Nov;128(3):342-50
pubmed: 20067534
N Engl J Med. 2021 Apr 22;384(16):1564-1565
pubmed: 33631064
Prostate. 2018 Sep;78(13):970-980
pubmed: 29786867
JCI Insight. 2021 Mar 8;6(5):
pubmed: 33539327
Cell Mol Life Sci. 2022 May 19;79(6):301
pubmed: 35588018
ACS Pharmacol Transl Sci. 2022 Jan 25;5(3):141-148
pubmed: 35774232
Vaccines (Basel). 2021 Apr 29;9(5):
pubmed: 33946736
Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2226-2231
pubmed: 30659154
Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17424-9
pubmed: 16299104
Front Microbiol. 2023 Jan 13;13:1111930
pubmed: 36713204
Int J Mol Sci. 2022 Sep 11;23(18):
pubmed: 36142454
Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2216814120
pubmed: 36603028
J Mol Cell Biol. 2021 Mar 10;12(12):916-932
pubmed: 33295606
Diabetes Care. 2020 Jul;43(7):1392-1398
pubmed: 32409502
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2604-9
pubmed: 20133784
Endocrinology. 2019 Jul 1;160(7):1600-1612
pubmed: 31070727
JAMA. 2023 Jan 3;329(1):39-51
pubmed: 36525245
Tissue Barriers. 2019;7(4):1669989
pubmed: 31578921
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
Front Physiol. 2014 Jul 15;5:259
pubmed: 25076911
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):12033-12038
pubmed: 29078377
Int J Cancer. 2018 Jun 1;142(11):2394-2404
pubmed: 29435973
Front Cell Infect Microbiol. 2019 Aug 30;9:311
pubmed: 31544067
Sci Rep. 2020 Jan 20;10(1):732
pubmed: 31959947
Elife. 2021 Nov 25;10:
pubmed: 34821549
Front Pharmacol. 2018 Feb 22;9:71
pubmed: 29520230
Elife. 2021 Dec 06;10:
pubmed: 34866574
Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):6067-6074
pubmed: 32123064
Clin Transl Immunology. 2021 Jul 05;10(7):e1310
pubmed: 34257968
Inflammopharmacology. 2021 Feb;29(1):91-100
pubmed: 33159646
Biomed Pharmacother. 2022 Feb;146:112554
pubmed: 34923341
Int Immunopharmacol. 2021 Nov;100:108125
pubmed: 34543980
Biomed Pharmacother. 2021 Oct;142:112067
pubmed: 34449310
Exp Eye Res. 2019 Apr;181:277-284
pubmed: 30831084
J Biochem Mol Toxicol. 2021 Oct;35(10):e22879
pubmed: 34369038
Lung. 2019 Oct;197(5):541-549
pubmed: 31392398
Cell Biol Toxicol. 2022 Aug;38(4):667-678
pubmed: 35015170
Cells. 2020 Oct 21;9(10):
pubmed: 33096674
Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):33-43
pubmed: 18084344
Int J Mol Sci. 2021 Jul 14;22(14):
pubmed: 34299155
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
Peptides. 2022 Apr;150:170716
pubmed: 34952135
EMBO Mol Med. 2021 Aug 9;13(8):e14150
pubmed: 34133077
Sci Rep. 2021 Jan 28;11(1):2530
pubmed: 33510215
Endocrinology. 2022 Dec 19;164(2):
pubmed: 36503995
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Mol Psychiatry. 2021 Dec;26(12):7465-7474
pubmed: 34331008
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18303-8
pubmed: 25489106
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945